CELL INTELLIGENCE · 肿瘤细胞治疗研究

PSMA1、PSMA5 和 PSMB2 作为预后生物标志物，并与 HCC 中肿瘤浸润白细胞相关

PSMA1, PSMA5, and PSMB2 serve as prognostic biomarkers and are correlated with tumor-infiltrating leukocytes in HCC.

多组学驱动的精准策略克服胃肠道恶性肿瘤中 CAR-T 治疗的局限性

Multi-Omics-Enabled Precision Strategies for Overcoming CAR-T Therapy Limitations in Gastrointestinal Malignancies.

基于配体-受体的新型 TWEAK CAR-T 通过靶向 FN14 对肝癌发挥强效抗肿瘤活性

Ligand-Receptor-Based Novel TWEAK CAR-T Exhibits Potent Antitumor Activity Against Liver Cancer by Targeting FN14.

NSUN2 介导的 m(5)C 修饰的代谢重编程通过限制 NK 细胞介导的细胞毒性促进肝细胞癌进展

Metabolic Reprogramming of NSUN2-Mediated m(5)C Modification Promotes the Progression of Hepatocellular Carcinoma by Restricting Natural Killer Cell-M

胸腺肽α-1 在肿瘤治疗中的作用：免疫调节机制、临床应用及转化前景

Thymosin α-1 in cancer therapy: Immunomodulatory mechanisms, clinical applications, and translational perspectives.

系统性治疗背景下 TACE-RFA 与单一疗法治疗复发性肝细胞癌的比较评估：一项倾向性评分匹配分析

Comparative evaluation of TACE-RFA versus monotherapies on a background of systemic therapy for recurrent hepatocellular carcinoma: a propensity score

对于接受 Lenvatinib 和 PD-1 抑制剂同步治疗的 rHCC 患者，序贯 TACE-RFA 治疗相比局部单一治疗提供了深远且独立的无进展生存期获益，且未增加患者不适。优越的局部肿瘤控制证明了预期的围手术期资源消耗初始增加是合理的。

血小板在肝细胞癌免疫微环境中的作用及其临床前景：一篇综合综述

The role of platelets in the hepatocellular carcinoma immune microenvironment and their clinical prospects: a comprehensive review.

共载黄芪甲苷 IV 与雷帕霉素的骨髓间充质干细胞来源外泌体纳米载体靶向调控肝细胞癌 PI3K/Akt/mTOR 通路

Astragaloside IV and rapamycin co-loaded bone marrow mesenchymal stem cell-derived exosome nanocarriers for targeted modulation of the PI3K/Akt/mTOR p

RAP@AST-IV/EXO NC 通过联合抑制 PI3K/Akt/mTOR 和诱导线粒体凋亡，代表了一种有前景且具有生物相容性的靶向 HCC 治疗策略。

一种通过设计的抗免疫抑制纳米调节剂和射频消融有效治疗癌症的新型联合疗法

A novel combination therapy for effective treatment of cancer by designed anti-immunosuppressive nanoregulator and radiofrequency ablation.

单细胞转录组图谱揭示酒精相关与非酒精相关肝细胞癌中不同的免疫生态系统

Single-cell transcriptomic profile unveils distinct immune ecosystems in alcohol- and nonalcohol-associated hepatocellular carcinoma.